P2-13 | Monday-1055

Adoption Of Alzheimer's Disease Biomarkers In Argentina Bridging The Gap Between Intended And Actual Clinical Use

Julian Fernandez Boccazzi, MD[1-2], Maria Belen Martin Escandell, MD[1], Josefina Escobar, MD[1], Ignacio Flores, MD[1] , Noelia Pontello, MD[1] , Galeno Rojas, PhD[1] and Santiago O'Neill, MD[1]

(1) Favaloro Foundation University Hospital, Buenos Aires, Argentina, (2) Ineco, Buenos Aires, Argentina

STUDY COHORT

- Cross-sectional online survey of clinicians in Argentina (n = 70)
- Physicians evaluating patients with cognitive impairment or dementia
- 80% Neurologists
- 44.3% Self-identified as dementia specialists
- 61% Practice in the metropolitan Buenos Aires area

HIGH WILLINGNESS TO USE AD BIOMARKERS

For AD Diagnosis	For Differential Diagnosis	For Treatment Monitoring (if DMTs available)
87% would use	83% would use	81% would use

INTENDED USE 81–87% WILLING TO USE BIOMARKERS → **IMPLEMENTATION GAP** → **ACTUAL USE** 37% HAVE EVER ORDERED AN AD BIOMARKER

High intention, low real-world use

KEY TAKE-HOME MESSAGES

- Most clinicians report high willingness (81–87%) to use AD biomarkers across clinical scenarios.
- Despite this, only 37% have actually ordered an AD biomarker.
- If blood-based biomarkers (BBMs) were available, 92.9% would order them.
- Limited access to DMTs is the main factor that negatively influences biomarker utilization (92.9%).
- Bridging this gap requires parallel advances in access, education, and health system readiness.

REAL-WORLD USE OF AD BIOMARKERS

Have ever ordered an AD biomarker?



Which modality was requested? (among those who ordered)



WHY IS BIOMARKER USE LIMITED?



WHO ORDERS BIOMARKERS? (MULTIVARIABLE ANALYSIS)

Dementia specialist vs. not specialist	OR 6.98 (95% CI 1.48–32.83)
Higher expertise (per 1-point increase)	OR 2.64 (95% CI 1.38–5.08)

METHODS (in brief)

Cross-sectional online survey
Multivariable logistic regression
Outcome: Prior ordering of AD biomarker (Yes/No)

DATA COLLECTED

Specialty, region, expertise
Perceived relevance, barriers
Prior use: BBMs, CSF, amyloid PET
Intended use in clinical scenarios

BIOMARKERS ASSESSED

Blood-based biomarkers (BBMs)
Cerebrospinal fluid (CSF)
Amyloid PET

ABBREVIATIONS

AD = Alzheimer's disease
BBMs = Blood-based biomarkers
DMTs = Disease-modifying therapies
CSF = Cerebrospinal fluid
PET = Positron Emission Tomography

jul.fboccazzi@gmail.com